作者:Sandeep Gawaskar、Dirk Schepmann、Alessandro Bonifazi、Bernhard Wünsch
DOI:10.1016/j.bmc.2014.10.004
日期:2014.12
Due to their beneficial side effect profile, NMDA receptor antagonists interacting selectively with the allosteric ifenprodil binding site of the GluN2B subunit are of major interest for the treatment of neurological and neurodegenerative disorders. A series of benzo[7]annulen-7-amines 6 was designed by conformational restriction of ifenprodil (1). At first the benzo[7]annulen-7-one 11 was prepared in a three-step synthesis comprising of a double Knoevenagel condensation of phthalaldehyde (7) with dimethyl 3-oxoglutarate (8), hydrogenation of 9 and saponification/decarboxylation of 10. Reductive amination of the ketone 11 with primary amines and NaBH(OAc)(3) led to the secondary amines 6a-d, cis-6h and trans-6i. The tertiary amines 6e-g were obtained by S(N)2-substitution of the nosylate 13. Although H-bond forming substituents in 2- and 5-position are missing, the amines 6 exhibit high affinity towards GluN2B containing NMDA receptors. A distance of four to five bond lengths between the basic amino moiety and the phenyl ring in the side chain appears to be optimal for high GluN2B affinity. The phenylcyclohexylamine cis-6h and the 4-benzylpiperidine 6g show the highest GluN2B affinities (K-i = 2.3 nM and 2.9 nM, respectively). With respect to selectivity against the PCP binding site, sigma(1) and sigma(2) receptors the phenylpiperazine 6f is the most promising GluN2B antagonist. (C) 2014 Elsevier Ltd. All rights reserved.